The potential of 5-methoxy-N,N-dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action

Alcohol use disorder (AUD) is described as a pattern of compulsive heavy drinking with loss of control despite negative consequences, and it is associated with neuroadaptations across basal ganglia, extended amygdala and prefrontal cortex that impair incentive salience, negative affect regulation and executive function. The authors note that AUD remains highly prevalent and costly, with modest efficacy of current pharmacological and psychosocial treatments, high relapse rates, and a widening treatment gap; few new medications have been approved in the past 20 years, motivating investigation of novel therapeutic approaches. This paper sets out to provide an initial synthesis of the extant literature on 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) as a candidate treatment for AUD, with a particular focus on putative therapeutic mechanisms. Tap and colleagues frame 5-MeO-DMT as a rapidly acting, short-duration classic psychedelic (typically 15–20 minutes after inhalation) that can occasion mystical experiences, ego-dissolution and increases in psychological flexibility and mindfulness, and they review human observational and clinical reports, neuroimaging studies, and preclinical work to identify mechanisms that could plausibly reduce AUD symptoms.

The extracted text does not present a formal Methods section detailing search strategy, inclusion criteria, databases, dates or risk-of-bias assessment. Rather, the paper functions as a narrative review that integrates findings from multiple types of evidence including surveys and observational studies in general population samples, a small number of clinical trials in healthy volunteers and individuals with treatment‑resistant depression, neuroimaging case reports and group studies (EEG and SPECT), and preclinical animal and organoid studies. The authors refer to a table summarising (pre)clinical studies and potential mechanisms, but the extraction does not include a methods protocol or explicit meta-analytic procedures. Within this narrative approach, the reviewers synthesise results under thematic headings: acute subjective effects (mystical experience, ego-dissolution), psychological processes (mindfulness, psychological flexibility), neuroimaging correlates, and preclinical neurobiological mechanisms (neural oscillations, neuroplasticity, anti-inflammatory effects, receptor pharmacology). When available, they report sample sizes and salient statistics from the cited studies (for example, survey and EEG sample sizes), but there is no description of systematic search, study selection, or quantitative pooling.

5-MeO-DMT acute subjective profile and safety: The authors summarise reports that 5-MeO-DMT is a natural or synthetic indole alkylamine that, when inhaled (commonly from toad secretions), produces rapid-onset peak effects within seconds and a brief subjective episode of around 15–20 minutes; intramuscular and intranasal routes have slower onsets and longer effects (up to ~60 minutes). The experience is characterised as intense, often content‑free, and dominated by transcendence, ego-dissolution, nonduality and strong affect (from love and awe to panic and terror), with relatively few visual phenomena. Observational and small clinical studies report mostly transient mild-to-moderate physiological and psychological adverse events (fear, anxiety, nausea, headache, etc.). Reactivations or flashbacks have been reported weeks later in an estimated 27% to 73% of respondents in survey work, typically described as positive or neutral; reports of psychosis are rare and may be confounded by concomitant ayahuasca use. Mystical experiences and addiction-relevant outcomes: Multiple surveys and case reports link the intensity of 5-MeO-DMT-induced mystical experiences to improvements in alcohol-related outcomes and mental health. A large survey (n = 515) found that 66% (n = 340) of respondents reported improvements in alcoholism following a 5-MeO-DMT experience. A retrospective online survey (n = 160) reported a significant association (p = 0.03) between mystical experience intensity and reduction in alcohol consumption. A case report of a veteran noted reduced craving at 5 days and sustained effects at 1 month. Survey evidence also links mystical experiences to reductions in symptoms of depression, PTSD and anxiety, which the authors relate to the self‑medication and negative‑reinforcement frameworks for AUD. Ego-dissolution, mindfulness and psychological flexibility: Ego-dissolution, strongly correlated with mystical experience, is reported in at least one survey (n = 42) to associate with lower depression and stress and greater life satisfaction. Small observational studies (n = 11; n = 42) and work in veteran samples (n = 51) indicate increases in facets of mindfulness (nonjudgement, awareness) and retrospective reports of psychological flexibility after 5-MeO-DMT; increases in psychological flexibility were predictive of reduced alcohol use in one retrospective survey and were strongly associated with changes in PTSD, MDD and anxiety in veterans. A prospective veteran study compared responders (n = 19) and non-responders (n = 26), finding greater decreases in symptom bother and alcohol use among responders, interpreted as evidence for improved acceptance processes. Neuroimaging findings: Two human neuroimaging studies are summarised. An EEG study in healthy volunteers (n = 23) reported acute fronto-parietal increases in gamma power (38–40 Hz), increases in theta (6–8 Hz) in most subjects, and a reversible increase in coherence across frequency bands, which the authors link to correlates of ego‑dissolution, mindfulness-related processes and reorganisation of executive control networks. A SPECT case report found increased perfusion in regions implicated in AUD three days after 5-MeO-DMT, but interpretation is limited because the subject had received ibogaine two days earlier. Preclinical neurobiology: Animal and organoid studies suggest multiple mechanisms. Electrophysiological work shows increases in theta (4–6 Hz) and gamma (30–60 Hz) in medial PFC and ventral hippocampus and increased beta-band coherence. Several studies demonstrate neuroplastic effects: single-dose increases in dendritic spine density in layer V pyramidal neurons of the PFC (absent in 5-HT2A knockout mice), medial frontal cortical spine increases lasting up to one month, and hippocampal neurogenesis and complex dendritic morphology changes. Human cerebral organoid studies indicate modulation of plasticity-related proteins and intracellular pathways (NMDAR, AMPAR, Ephrin B2). Anti-inflammatory effects have been observed via inhibition of NF-κB signalling and sigma-1 receptor engagement, reducing proinflammatory cytokines (IL-1β, IL-6, TNFα, IL-8) and increasing IL-10 in some models; a small human observational study (n = 11) reported anti-inflammatory signals that were not significantly related to mental health ratings. Pharmacologically, 5-MeO-DMT shows affinity for serotonin receptors (notably 5-HT1A and 5-HT2A), with 5‑HT2A agonism implicated in antidepressant-like effects, and preclinical evidence of downregulation of metabotropic glutamate receptor 5, a receptor implicated in alcohol reward and craving.

Tap and colleagues conclude that the therapeutic potential of 5-MeO-DMT for AUD is currently hypothetical and primarily supported by observational and preclinical data; causality has not been established because most human reports are non-randomised, often retrospective, and drawn from general population samples. They identify the strongest human evidence for 5-MeO-DMT's capacity to occasion mystical experiences, which may reduce AUD symptoms indirectly by alleviating negative affect and comorbid psychiatric conditions that drive self‑medication and relapse risk. Ego-dissolution is discussed as a related psychological mechanism that may alter the narrative sense of self, reduce self-focused negative affect and increase self-compassion, potentially weakening negative‑reinforcement pathways that sustain drinking. Neurobiological mechanisms are positioned as complementary: short‑term changes in neural oscillations (increased gamma and theta, greater coherence) could underlie subjective phenomena such as ego-dissolution and improved top‑down control; neuroplasticity in prefrontal and hippocampal circuits could support longer-term improvements in mood and executive function; anti‑inflammatory effects and receptor-level actions (5-HT2A agonism, mGluR5 downregulation) offer additional mechanistic plausibility. However, the authors acknowledge important uncertainties and methodological limitations across the evidence base, including small samples, heterogeneous measures of AUD and mental health, confounding (for example, concurrent ibogaine use), and reliance on self-report. To address these gaps, the paper recommends rigorous future research: randomised, placebo-controlled clinical trials with standardised AUD assessment tools (Alcohol Use Disorder Identification Test, Timeline Follow-Back, Penn Alcohol Craving Scale), measurement of ego-dissolution (Ego Dissolution Inventory) as a potential moderator, systematic dosing studies to characterise dose–response of mystical effects, and investigation of psychotherapeutic frameworks (including psychodynamic approaches) that might interact with 5‑MeO‑DMT. Translational work is also urged: addiction-relevant animal models that directly assess incentive salience, negative affect and executive function, and mechanistic studies probing TrkB and mTOR signalling, given their roles in neuroplasticity with other serotonergic psychedelics. Overall, the authors call for controlled clinical and translational research to establish whether the psychological and neurobiological mechanisms reviewed translate into clinically meaningful reductions in alcohol use and relapse.